All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 16:01, 18 May 2024 Rithish Nimmagadda talk contribs created page Ritlecitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...")
- 17:21, 17 May 2024 Rithish Nimmagadda talk contribs created page Quizartinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...")
- 16:40, 17 May 2024 Rithish Nimmagadda talk contribs created page Lotilaner (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...")
- 14:40, 16 May 2024 Alen Antony talk contribs created page Leniolisib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}")
- 10:11, 16 May 2024 Muhammad Waleed talk contribs created page Avacincaptad pegol (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...")
- 09:31, 16 May 2024 Muhammad Waleed talk contribs created page File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 09:31, 16 May 2024 Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 07:06, 16 May 2024 Alara E. Dagsali talk contribs created page Diclofenac Patch (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...")
- 06:42, 16 May 2024 Alara E. Dagsali talk contribs created page Cortisone Acetate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...")
- 06:32, 16 May 2024 Alara E. Dagsali talk contribs created page Clocortolone Pivalate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...")
- 06:20, 16 May 2024 Alara E. Dagsali talk contribs created page Scorpion (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...")
- 10:58, 15 May 2024 Alara E. Dagsali talk contribs created page Lodoxamide (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...")
- 23:48, 13 May 2024 Alen Antony talk contribs created page Fezolinetant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}")
- 20:38, 13 May 2024 Muhammad Waleed talk contribs created page Talquetamab-tgvs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...")
- 14:50, 13 May 2024 Alen Antony talk contribs created page Nirsevimab-alip (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...")
- 19:35, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1208.jpeg
- 19:35, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1207.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1204.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg
- 19:30, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1202.jpeg
- 19:30, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg
- 19:28, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1200.jpeg
- 19:28, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg
- 19:24, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1214.jpeg
- 19:24, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg
- 05:30, 12 May 2024 Kosar Doraghi talk contribs created page Somatrogon-ghla (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...")
- 05:15, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1198.jpeg
- 05:15, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg
- 05:13, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1215.jpeg
- 05:13, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg
- 20:21, 11 May 2024 Rithish Nimmagadda talk contribs created page Elfabrio (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...")
- 19:36, 11 May 2024 Rithish Nimmagadda talk contribs created page Exxua (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}")
- 13:10, 9 May 2024 Rithish Nimmagadda talk contribs created page Epcoritamab-bysp (Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}")
- 10:37, 9 May 2024 Hafiza Amna Qadeer talk contribs created page FUTIBATINIB (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER, MD |OTC=Yes |genericName=FUTIBATINIB |aOrAn=a |drugClass=Kinase Inhibitor |indicationType=treatment |indication=* of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |adverseReactions=1* Nail Toxicity, stomatitis, dry skin, dry eye, alopecia 2* Musculos...")
- 04:57, 9 May 2024 Alen Antony talk contribs created page Sotagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}")
- 21:32, 8 May 2024 Kosar Doraghi talk contribs created page EXXUA (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Gepirone |aOrAn=a |drugClass=extended-release tablets |indicationType=treatment |indication=major depressive disorder (MDD) in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, nausea, insomnia, abdominal pain, and dyspepsia |blackBoxWarningTitle=WARNING: SUICIDAL THOUGHTS AND BEHAVIORS |blackBoxWarningBody=SEE FULL PRESCRIBING INFORMATION FOR...")
- 21:27, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1195.jpeg
- 21:27, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1195.jpeg
- 21:26, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1196.jpeg
- 21:26, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1196.jpeg
- 21:19, 8 May 2024 Kosar Doraghi talk contribs created page File:IMG 1194.jpeg
- 21:19, 8 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1194.jpeg
- 17:11, 8 May 2024 Imam Ali Shah talk contribs created page File:Screenshot (245).jpg
- 17:11, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Screenshot (245).jpg
- 17:02, 8 May 2024 Imam Ali Shah talk contribs created page File:RCR logo.png
- 17:02, 8 May 2024 Imam Ali Shah talk contribs uploaded File:RCR logo.png
- 16:30, 8 May 2024 Imam Ali Shah talk contribs uploaded a new version of File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg (Pre-contrast CT scan of the abdomen and pelvis depicts an irregular nodular margin of the liver (green arrowhead), hypertrophy of the caudate lobe (orange arrow), and the presence of ascites (red arrow).)
- 16:21, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
- 16:21, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png
- 16:19, 8 May 2024 Imam Ali Shah talk contribs created page File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:19, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:18, 8 May 2024 Imam Ali Shah talk contribs created page File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:18, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:17, 8 May 2024 Imam Ali Shah talk contribs created page File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 16:17, 8 May 2024 Imam Ali Shah talk contribs uploaded File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg
- 14:44, 8 May 2024 Rithish Nimmagadda talk contribs created page Template:VSRN (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]")
- 14:20, 8 May 2024 Rithish Nimmagadda talk contribs created page User:Rithish Nimmagadda (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India")
- 14:10, 8 May 2024 Rithish Nimmagadda talk contribs created page FRUZAQLA (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...")
- 13:32, 8 May 2024 Rithish Nimmagadda talk contribs created page Fruzaqla (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}")
- 01:53, 8 May 2024 Edzelco talk contribs created page File:LOQTORZI Dosage.png
- 01:53, 8 May 2024 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
- 17:27, 7 May 2024 Alen Antony talk contribs created page Zuranolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...")
- 22:57, 3 May 2024 Kosar Doraghi talk contribs created page Xacduro- sulbactam and durlobactam (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...")
- 18:20, 3 May 2024 Alen Antony talk contribs created page Perfluorhexyloctane (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}")
- 15:29, 2 May 2024 Alen Antony talk contribs created page Trofinetide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}")
- 03:29, 2 May 2024 Alen Antony talk contribs created page Zavegepant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...")
- 21:51, 1 May 2024 Alen Antony talk contribs created page Omaveloxolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=omaveloxolone }}")
- 15:46, 1 May 2024 Kosar Doraghi talk contribs created page Nirsevimab (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=Nirsevimab |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season |hasBlackBo...")
- 15:31, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1185.jpeg
- 15:31, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1185.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs created page File:IMG 1187.jpeg
- 15:29, 1 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1187.jpeg
- 14:19, 1 May 2024 User account Rithish Nimmagadda talk contribs was created by Alberto Castro Molina talk contribs
- 18:57, 30 April 2024 Alara E. Dagsali talk contribs created page Isosulfan Blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...")
- 18:46, 30 April 2024 Alara E. Dagsali talk contribs created page Ibuprofen Lysine (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...")
- 18:27, 30 April 2024 Alara E. Dagsali talk contribs created page Prussian blue (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...")
- 18:14, 30 April 2024 Alara E. Dagsali talk contribs created page Botulism Antitoxin (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...")
- 15:23, 29 April 2024 Alara E. Dagsali talk contribs created page Trastuzumab emtansine (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...")
- 17:32, 26 April 2024 User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs
- 22:39, 25 April 2024 Alara E. Dagsali talk contribs created page User:AED (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...")
- 15:23, 25 April 2024 Alen Antony talk contribs created page Daprodustat (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
- 23:04, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1177.jpeg
- 23:04, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs created page File:IMG 1176.jpeg
- 22:59, 24 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg
- 21:21, 24 April 2024 Alara E. Dagsali talk contribs created page Template:AlaraE.Dagsali (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]")
- 21:14, 24 April 2024 Alara E. Dagsali talk contribs created page Tranexamic (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
- 21:06, 24 April 2024 Alen Antony talk contribs created page Bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
- 15:32, 23 April 2024 User account Malaika Hassan talk contribs was created by Alberto Castro Molina talk contribs
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs created page File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:44, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs created page File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 18:43, 22 April 2024 Alara E. Dagsali talk contribs uploaded File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG
- 03:48, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1052.jpeg
- 03:48, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1052.jpeg
- 03:47, 21 April 2024 Kosar Doraghi talk contribs created page BRENZAVVY- bexagliflozin (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
- 03:43, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1050.jpeg
- 03:43, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1050.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1051.jpeg
- 03:40, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1051.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs created page File:IMG 1049.jpeg
- 03:34, 21 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1049.jpeg
- 16:05, 20 April 2024 Imam Ali Shah talk contribs created page Template:IAS (Created page with "Associate Editor-In-Chief: Imam Ali Shah, MBBS; Chandka Medical College, Larkana Pakistan")
- 16:30, 19 April 2024 Kosar Doraghi talk contribs created page Sparsentan (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
- 16:24, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1046.jpeg
- 16:24, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1045.jpeg
- 16:14, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg
- 16:11, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1047.jpeg
- 16:11, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg
- 16:05, 19 April 2024 Kosar Doraghi talk contribs created page File:IMG 1044.jpeg
- 16:05, 19 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg
- 19:33, 17 April 2024 Hafiza Amna Qadeer talk contribs created page SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (Created blank page)
- 08:08, 17 April 2024 Edzelco talk contribs created page Elranatamab-bcmm (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Palovarotene (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Pozelimab-bbfg (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Motixafortide (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Momelotinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:06, 17 April 2024 Edzelco talk contribs created page Cipaglucosidase alfa-atga (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Etrasimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Zilucoplan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Bimekizumab (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Vamorolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Mirikizumab-mrkz (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:03, 17 April 2024 Edzelco talk contribs created page Toripalimab-tpzi (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:02, 17 April 2024 Edzelco talk contribs created page Fruquintinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
- 07:52, 17 April 2024 Edzelco talk contribs created page Taurolidine, heparin (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
- 07:43, 17 April 2024 Edzelco talk contribs created page Repotrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
- 07:32, 17 April 2024 Edzelco talk contribs created page Efbemalenograstim alfa-vuxw (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
- 05:50, 16 April 2024 Edzelco talk contribs created page Capivasertib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
- 05:27, 16 April 2024 Edzelco talk contribs created page Iptacopan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
- 07:24, 15 April 2024 Edzelco talk contribs created page Vutrisiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
- 20:06, 11 April 2024 User account Bilal Farhat Ali talk contribs was created by Alberto Castro Molina talk contribs
- 19:20, 10 April 2024 Kosar Doraghi talk contribs created page File:IMG 1037.jpeg
- 19:20, 10 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 1037.jpeg
- 23:28, 3 April 2024 Kosar Doraghi talk contribs created page File:IMG 0918.jpeg
- 23:28, 3 April 2024 Kosar Doraghi talk contribs uploaded File:IMG 0918.jpeg
- 20:13, 27 March 2024 M. Arsalan Bashir talk contribs created page User:M. Arsalan Bashir (Created page with "I’m an aspiring Neuroscientist and Neurology MD candidate, having earned my MBBS degree from Ziauddin University. My journey has led me to research, where I am wholeheartedly committed to enhancing treatment methods and increasing knowledge to challenge the stigma often linked with neurological conditions.") Tag: Visual edit
- 11:08, 27 March 2024 Imam Ali Shah talk contribs created page File:Bismuth Subnitrate Package and Label Display Panel.jpg
- 11:08, 27 March 2024 Imam Ali Shah talk contribs uploaded File:Bismuth Subnitrate Package and Label Display Panel.jpg
- 09:51, 27 March 2024 Imam Ali Shah talk contribs created page Bismuth subnitrate (Created page with "dasda") Tag: Visual edit
- 09:13, 26 March 2024 Imam Ali Shah talk contribs created page User:Imam Ali Shah (Created page with "=='''Imam Ali Shah, MBBS'''== Contact:Email: imamshah.med@gmail.com ==Medical Education== *'''2017-2022''' **MBBS Chandka Medical College, Pakistan ==Professional Affiliations== *Profesional Aff...")
- 08:33, 21 March 2024 Alara E. Dagsali talk contribs created page Norelgestromin (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=NORELGESTROMIN AND ETHINLY ESTRADIOL patch |indicationType=prevention |indication=Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m for whom a combined hormonal contraceptive is appropriate. |hasBlackBoxWarning=Yes |adverseReactions=The following serious adverse reactions with the use of co...")
- 05:58, 21 March 2024 Kosar Doraghi talk contribs created page File:IMG 0885.jpeg
- 05:58, 21 March 2024 Kosar Doraghi talk contribs uploaded File:IMG 0885.jpeg
- 23:07, 19 March 2024 Kosar Doraghi talk contribs created page Ryzneuta (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]] |genericName=RYZNEUTA -Efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=treatment |indication=and decrease the incidence of infection, as manifested by [febrile neutropenia], in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |h...")
- 10:01, 12 March 2024 Hafiza Amna Qadeer talk contribs created page Rezafungin (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER |OTC=Yes |genericName=REZAFUNGIN |aOrAn=an |drugClass=echinocandin antifungal |indicationType=treatment }}")
- 17:24, 5 March 2024 User account Imam Ali Shah talk contribs was created by Alberto Castro Molina talk contribs
- 17:17, 5 March 2024 User account M. Arsalan Bashir talk contribs was created by Alberto Castro Molina talk contribs
- 18:02, 3 March 2024 Marshallsumter talk contribs created page Non-degenerate nucleotides per response element (Created page with " {| class="wikitable sortable" |+ Number of non-degenerate nucleotides versus number of response elements |- ! Number of nucleotides !! Letters of nucleotides !! Number of response elements !! Average ± deviation !! Order of list |- | 1 || A || 295 || 295.0 ± 0.0 || 1 |- | 1 || T || 285 || - || 1 |- | 1 || G || 286 || - || 3 |- | 1(4) || C || 300 || 291.5 ± 6 || 5 |- | 2 || AA || 105 || 105 ± 0.0 || 1 |- | 2 || AT || 105 || 105 ± 0.0 || 1 |- | 2 || TA || 74 |...")
- 02:16, 29 February 2024 Alen Antony talk contribs created page Lecanemab-irmb (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lecanemab-irmb |aOrAn=a |drugClass=recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody |indicationType=treatment |indication=Alzheimer’s disease. This drug is ideally initiated during the early phase of dementia or mild cognitive impairment (which was the population tested in the clinical trials of this drug). |hasBlackBoxWarning=Yes |adverseReactions=Amyloid Related Imaging Abnorma...")
- 02:40, 28 February 2024 Kosar Doraghi talk contribs created page Vonoprazan fumarate (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=vonoprazan fumarate |aOrAn=a |drugClass=potassium-competitive acid blocker |indicationType=treatment |indication=all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *in combinatio...")
- 21:36, 23 February 2024 Kosar Doraghi talk contribs created page Nedosiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nedosiran |aOrAn=an |drugClass=LDHA-directed small interfering RNA |indicationType=treatment |indication=lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥ 30 mL/min/1.73 m2 |adverseReactions=injection site reactions |fdaLIADAdult=RIVFLOZA Injection 160 mg/mL is a clear, colorless-t...")
- 21:25, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0866.jpeg
- 21:25, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0866.jpeg
- 21:24, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0864.jpeg
- 21:24, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0864.jpeg
- 21:21, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0858.jpeg
- 21:21, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0858.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0861.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0861.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0860.jpeg
- 21:20, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0860.jpeg
- 21:19, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0859.jpeg
- 21:19, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0859.jpeg
- 21:17, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0867.jpeg
- 21:17, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0867.jpeg
- 21:11, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0857.jpeg
- 21:11, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0857.jpeg
- 21:09, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0856.jpeg
- 21:09, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0856.jpeg
- 21:06, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0855.jpeg
- 21:06, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0855.jpeg
- 21:05, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0853.jpeg
- 21:05, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0853.jpeg
- 20:53, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0852.jpeg
- 20:53, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0852.jpeg
- 04:16, 23 February 2024 Kosar Doraghi talk contribs created page Nirogacestat (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=nirogacestat |aOrAn=a |drugClass=gamma secretase inhibitor |indicationType=treatment |indication=adult patients with progressing desmoid tumors who require systemic treatment |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection and [...")
- 04:05, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0851.jpeg
- 04:05, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0851.jpeg
- 04:00, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0848.jpeg
- 04:00, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0848.jpeg
- 03:59, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0850.jpeg
- 03:59, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0850.jpeg
- 03:57, 23 February 2024 Kosar Doraghi talk contribs created page File:IMG 0847.jpeg
- 03:57, 23 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0847.jpeg
- 16:45, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Sandbox:MNH (Created page with "=====bold kardan subtitle=====")
- 13:31, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Birch triterpenes (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=birch triterpenes }}")
- 13:24, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Eplontersen (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=Eplontersen |aOrAn=a |drugClass=transthyretin-directed antisense oligonucleotide |indicationType=treatment |indication=WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=Most common adverse reactions (that occurred in at least 9% of patients treated with WAINUA) were vitamin A decreased and vomiting. |fdaLIADAdult...")
- 12:33, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Template:MNH (Created page with "Mohammad Nikoohemmat, M.D.[mailto:mohammadnikoo1375@gmail.com]")
- 16:38, 21 February 2024 Badgettrg talk contribs created page Template:Math2 (Created page with "<span class="texhtml {{#if:{{{big|}}}{{{size|}}}|texhtml-big}}" {{#if:{{{big|}}}{{{size|}}}|style="font-size:{{{size|165%}}};"}}>{{{1}}}</span><!-- -->{{#invoke:Check for unknown parameters|check | unknown = {{main other|_VALUE_}} | showblankpositional=1 | preview = unknown parameter "_VALUE_" (consider using <code>{{!}}1=</code>, <code><nowiki>{{!}}</nowiki></code>, <code><nowiki>{{=}}</nowiki></code>) | 1 | big | si...")
- 06:21, 21 February 2024 Alen Antony talk contribs created page Olutasidenib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Olutasidenib |aOrAn=a |drugClass=isocitrate dehydrogenase-1 (IDH1) inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, mucositis, arthralgia, fatigue, pyrexia...")
- 14:13, 20 February 2024 Badgettrg talk contribs created page Treatment outcome (Created page with "{{SI}} {{RGB}} In Quality of Health Care, '''{{PAGENAME}}''' is defined as "Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series."<ref>{{MeSH}}</ref> ==Statistical methods== * The minimal clinically important differences (MCID) has been proposed as >0.5 standard deviation imp...")
- 15:11, 19 February 2024 Matt Pijoan talk contribs created page Template:Image (Created page with "<templatestyles src="Image/styles.css"/><div class="t-image {{#ifeq:{{{padding|}}}|no||t-image-padding}}" {{#if:{{{width|}}}|style="max-width:{{{width}}}%"}}> [[File:{{{file|File:MattP(1).png}}}|{{{imagewidth|400}}}px|{{#ifeq:{{{border|}}}|yes|border{{!}}}}alt={{{caption|}}}|{{#if:{{{link|}}}|link={{{link|}}}}}]]{{#if: {{{caption|}}}| <p class="t-image-caption"> {{{caption}}} </p>}} </div><noinclude> {{documentation|content= {{Uses TemplateStyles|Template:Image/styles.cs...")
- 16:17, 18 February 2024 Badgettrg talk contribs created page Back pain monitoring response to therapy (Created page with "__NOTOC__ {{Back pain}} {{CMG}} {{AE}} {{ZMalik}} ==Overview== The Oswestry low back pain disability questionnaire (ODQ) can measure the response to therapy.<ref name="pmid6450426">{{cite journal| author=Fairbank JC, Couper J, Davies JB, O'Brien JP| title=The Oswestry low back pain disability questionnaire. | journal=Physiotherapy | year= 1980 | volume= 66 | issue= 8 | pages= 271-3 | pmid=6450426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi...")
- 03:15, 16 February 2024 Kosar Doraghi talk contribs created page Lasmiditan (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Lasmiditan (REYVOW) |aOrAn=a |drugClass=serotonin (5-HT) 1F receptor agonist |indicationType=treatment |indication=migraine with or without aura in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, fatigue, paresthesia, and sedation |blackBoxWarningTitle=Warning |blackBoxWarningBody=Driving Impairment: *Central Nervous System (CNS) Depression: Do not use in combination...")
- 03:03, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0837.jpeg
- 03:03, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0837.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0839.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0839.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0838.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0838.jpeg
- 06:30, 15 February 2024 Alen Antony talk contribs created page Lenacapavir (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lenacapavir }}")
- 02:00, 15 February 2024 Alara E. Dagsali talk contribs created page 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) (Created page with "{{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines f...")
- 01:01, 15 February 2024 Kosar Doraghi talk contribs created page Ponesimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Ponesimod (PONVORY) |aOrAn=a |drugClass=sphingosine 1-phosphate receptor modulator |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=upper respiratory tract infection, hepatic transaminase elevation, and ...")
- 00:56, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0834.jpeg
- 00:56, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0834.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0833.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0833.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0832.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0832.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0829.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0829.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0831.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0831.jpeg
- 21:25, 14 February 2024 Alen Antony talk contribs created page Tirzepatide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=tirzepatide |aOrAn=a |drugClass=glucagon-like peptide-1 (GLP-1) receptor agonist |indicationType=treatment |indication=type 2 diabetes mellitus in adults in adjunct to diet and exercise. |hasBlackBoxWarning=Yes |adverseReactions=pancreatitis,hypoglycemia with concomitant use of insulin or insulin secretagogues, acute kidney injury, severe gastrointestinal disease, acute gallbladder disease, dia...")
- 18:30, 14 February 2024 Kosar Doraghi talk contribs created page Dasiglucagon (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Dasiglucagon (ZEGALOGUE) |aOrAn=an |drugClass=anti-hypoglycemic |indicationType=treatment |indication=severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, headache, diarrhea, and injection site pain |blackBoxWarningTitle=Allergic reactions |blackBoxWarningBody=increase in blood pressure in Patients wi...")
- 18:17, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0828.jpeg
- 18:17, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0828.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0827.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0827.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0822.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0822.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0826.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0826.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0824.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0824.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0823.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0823.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0820.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0820.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0819.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0819.jpeg
- 07:05, 14 February 2024 Alen Antony talk contribs created page Spesolimab-sbzo (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Spesolimab-sbzo |drugClass=humanized monoclonal Immunoglobulin G1 antibody |indicationType=treatment |indication=generalized pustular psoriasis (GPP) flares in adults. |adverseReactions=infections, nausea, vomiting, headache, fatigue, Infusion site hematoma and bruising. |fdaLIADAdult=SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is administer...")
- 21:57, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0813.jpeg
- 21:57, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0813.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0812.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0812.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0817.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0817.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0818.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0818.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0816.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0816.jpeg
- 21:47, 13 February 2024 Kosar Doraghi talk contribs created page Vericiguat (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VERQUVO-vericiguat |aOrAn=a |drugClass=soluble guanylate cyclase (sGC) stimulator |indicationType=treatment |indication=heart failure with reduced ejection fraction (HFrEF), reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less t...")
- 21:43, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0815.jpeg
- 21:43, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0815.jpeg
- 03:20, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0810.jpeg